ArticlePediatric transplantation2026
Dosing, Safety, and Tolerability of Extended-Release Tacrolimus in Pediatric and Young Adult Solid Organ Transplant Recipients.
Article in Pediatric transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dosing, Safety, and Tolerability of Extended-Release Tacrolimus in Pediatric and Young Adult Solid Organ Transplant Recipients.Pediatric transplantation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundComplicated immunosuppression regimens can contribute to non-adherence in pediatric solid organ transplant (SOT) recipients. Once-daily tacrolimus formulations, such as LCP-tacrolimus (LCPT), may help simplify dosing, but pediatric data on dosing, safety, and early tolerability are limited.
methodsWe conducted a single center retrospective cohort study of SOT recipients prescribed LCPT from December 2016 to July 2024 at our institution. LCPT:IR-Tac daily dosing ratios were calculated. The frequency of laboratory-associated adverse events (AE) and of new patient-reported adverse events in the first 90 days were collected and compared across pediatric- and adult-aged SOT recipients.
resultsNinety-one SOT recipients were prescribed LCPT at a median age of 16.8 years (range 8.4-24.1) and 75 months after transplant (range 0.25-217). Among 53 patients who were therapeutic on both IR-Tac and LCPT, the median daily dosing ratio of LCPT:IR-Tac was 0.75 (range 0.33-1.5) for pediatric patients and 0.75 (IQR: 0.46-1.33) for adults. Eleven (5 patient-reported and 6 laboratory) AEs were identified, none of which resulted in cessation of LCPT therapy. There were no significant differences in the frequency of AEs between children and adults.
conclusionsLCPT was well tolerated and typically required about a 25% dose reduction compared with IR-tacrolimus, though conversion ratios varied widely. These findings offer practical guidance for LCPT dosing in pediatric transplant care and highlight the need for individualized titration and monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.